Avanir Pharmaceuticals, Inc. (AVNR) Posts Better-Than-Expected Q1 Results
AVNR Hot Sheet
Revenue Growth %: +614.3%Financial Fact:
Interest income: 7.88K
Today's EPS Names:
TARO, BRLI, TLB, More
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) reported Q1 EPS of ($0.12), $0.01 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $7.2 million versus the consensus estimate of $6.49 million.
For earnings history and earnings-related data on Avanir Pharmaceuticals, Inc. (AVNR) click here.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
For earnings history and earnings-related data on Avanir Pharmaceuticals, Inc. (AVNR) click here.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- UPDATE: Ralph Lauren Corp (RL) Reports Solid Q4 Results; Guides FY13 Sales
- UPDATE: Nomura Securities Upgrades ASML Inc. (ASML) to Buy; Revenue Outlook Underestimated
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
